Contract Manufacturing Organization (CMO)

Overview of the CDMO value chain

The segmentation of the pharmaceutical CDMO value chain follows three major categories:

  • drug and process development,
  • active pharmaceutical ingredient (API) production and
  • finished dosage form (FDF) .

Close to these CDMO core segments are drug discovery and development support, provided by contract research organizations (CROs) as well as contract packaging services, which are provided by CDMOs or specialized contract packaging organizations (CPOs).

Tasks outsourced to CDMOs by pharmaceutical companies cover the entire value chain of a drug’s life cycle, from drug development and preclinical and clinical trials to commercial production. While traditional CMO services were centered on their core competencies in API bulk manufacturing and formulation, CDMOs have also moved into adjacent segments along the manufacturing value chain. These tasks, which in the past have been covered by pharmaceutical companies themselves or by contract research organizations, include medical chemistry, support for preclinical in vitro and in vivo studies, and formulation and process analytics development.

The Problem facing in Chinese domestic market

The year 2018 have been proven to be the pivotal year for contract manufacturing and development organisations (CDMO). With rapid development in potent compounds, and ambitious plans fueled by  investments from major Private Equity firms, many of these facilities have achieved unprecedent growth with no signs of slowing down.

​As old as it goes, the sole hindrance for a CDMO renaissance in China is still trust. 

Our Services:

  • Scouting for GMP Partners
  • Locating ideal Development Zone for new site
  • Negotiating favorable provisions with local Government

For specific offer, Please contact this Email or fill in contact form.

en_USEnglish